Type 2 Diabetes and the Multifaceted Gut-X Axes

Area of Science:

• Metabolic disease research
• Gut microbiome and health
• Endocrinology

Background:

• Type 2 diabetes (T2D) is characterized by hyperglycemia, insulin resistance, and impaired insulin secretion.
• Emerging evidence implicates the gut microbiome and enteroendocrine cells in T2D pathophysiology.
• Gut dysbiosis and increased permeability are linked to obesity, insulin resistance, and beta-cell dysfunction.

Purpose of the Study:

• To comprehensively review gut-mediated crosstalk with metabolic organs in T2D.
• To examine key molecular mechanisms driving these gut-organ interactions.
• To discuss clinical implications and future research directions for targeting Gut-X axes.

Main Methods:

• Systematic literature search (2015-2025) in PubMed, Scopus, and Web of Science.
• Screening of over 150 high-impact publications following PRISMA guidelines.
• Data extraction on gut microbiota, hormones, inflammatory mediators, and organ-specific outcomes in T2D.

Main Results:

• T2D involves perturbations in multiple Gut-X axes, including Gut-Pancreas, Gut-Endocrine, Gut-Liver, and Gut-Kidney.
• Key mechanisms include incretins, bile acids, SCFAs, and endotoxins modulating inflammation and metabolism.
• Shared pathways involve SCFAs improving insulin sensitivity and LPS driving inflammation.

Conclusions:

• An integrated understanding of Gut-X axes reveals novel therapeutic opportunities for T2D.
• Modulating the gut microbiome can improve glycemic control and ameliorate complications.
• Further human studies are needed to translate these findings into clinical practice.